Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Trevor Motter

Physician Assistant Henderson, NV Physician Assistant

NPI 1194350983 CMS profile 11137782

100 N Green Valley Pkwy Ste 110, Henderson, NV 89074

Open in the dashboard

General payments

$3,986

189 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Trevor Motter of Henderson, NV is reported in the CMS Open Payments database as having received $3,986 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $862 50
2022 General $1,155 64
2021 General $1,969 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trevor Motter
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Trevor Motter were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Trevor Motter Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,969 $132 $37–$438 $132
2022 $1,155 $155 $48–$522 $149
2023 $862 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Biohaven Pharmaceuticals, Inc. $920 10 payments
  2. AstraZeneca Pharmaceuticals LP $709 42 payments
  3. AbbVie, Inc. $378 25 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $263 14 payments
  5. Pfizer Inc. $258 16 payments
  6. Novo Nordisk Inc $212 11 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $140 11 payments
  8. Janssen Pharmaceuticals, Inc $113 1 payment
  9. Amgen Inc. $100 5 payments
  10. Merck Sharp & Dohme Corporation $97 5 payments
  11. Other $795 49 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $3,186 188 payments
  2. Consulting Fee $800 1 payment
Products named General payments · program years 2021–2023
  1. NURTEC ODT Primary Care $1,060 21 payments
  2. FARXIGA $381 24 payments
  3. BREZTRI $293 16 payments
  4. JARDIANCE $208 12 payments
  5. PAXLOVID $169 11 payments
  6. NURTEC ODT Pain $136 9 payments
  7. UBRELVY $136 10 payments
  8. SPRAVATO $113 1 payment
  9. RYBELSUS $102 5 payments
  10. XIFAXAN $84 5 payments
  11. Other $2,173 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

2,156

Median for Physician Assistant: 241

Drug cost

$153,052

Median for Physician Assistant: $4,110

Branded share of claims

11.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 49 $49,443
Rybelsus Semaglutide Brand 15 $31,178
Eliquis Apixaban Brand 14 $20,750
Jardiance Empagliflozin Brand 12 $18,612
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 19 $13,257
Levothyroxine Sodium Generic 151 $1,681
Atorvastatin Calcium Generic 166 $1,266
Rosuvastatin Calcium Generic 101 $1,249
Albuterol Sulfate Hfa Albuterol Sulfate Brand 44 $907
Zolpidem Tartrate Generic 88 $756

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$22,135

Medicare's payments for the services billed

Medicare patients

142

Average age 73

Services billed

352

84 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 37%
Arthritis 37%
Chronic kidney disease 30%
Ischemic heart disease 27%
COPD 18%
Depression 18%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record